<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11437395</article-id><article-id pub-id-type="pmc">2363923</article-id><article-id pub-id-type="pii">6691861</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.1861</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ueoka</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tanimoto</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kiura</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tabata</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Takigawa</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Segawa</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Takata</surname><given-names>I</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Eguchi</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Okimoto</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Harita</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kamei</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Shibayama</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Watanabe</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Hiraki</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Harada</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Internal Medicine II, Okayama University Medical School, 2-5-1 Shikatacho, Okayama, 700-8558, Japan</aff><aff id="aff2"><label>2</label>Department of Respiratory Medicine, National Shikoku Cancer Center</aff><aff id="aff3"><label>3</label>Department of Internal Medicine, Kawasaki Medical School, Kawasaki Hospital</aff><aff id="aff4"><label>4</label>Department of Internal Medicine, Chugoku Central Hospital</aff><aff id="aff5"><label>5</label>Department of Internal Medicine, Sumitomobesshi Hospital</aff><aff id="aff6"><label>6</label>Department of Internal Medicine, Okayama Health Foundation Hospital</aff><aff id="aff7"><label>7</label>Department of Internal Medicine, Okayama Red Cross General Hospital</aff><pub-date pub-type="ppub"><month>07</month><year>2001</year></pub-date><volume>85</volume><issue>1</issue><fpage>9</fpage><lpage>13</lpage><history><date date-type="received"><day>16</day><month>10</month><year>2000</year></date><date date-type="rev-recd"><day>19</day><month>03</month><year>2001</year></date><date date-type="accepted"><day>27</day><month>03</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>A phase II study of fractionated administration of irinotecan (CPT-11) and cisplatin (CDDP) in patients with non-small-cell lung cancer (NSCLC) was conducted. Between January 1996 and January 1998, 44 previously untreated patients with stage IIIB or IV NSCLC were enrolled. CDDP at a dose of 60&#x02008;mg m<sup>&#x02013;2</sup>was given first and followed by CPT-11 at a dose of 50&#x02008;mg m<sup>&#x02013;2</sup>. Both drugs were given by 1-hour infusion on days 1 and 8, and repeated every 4 weeks up to 4 cycles. 42 patients were evaluated for response and 44 for survival and toxicity. 20 patients (48&#x00025;: 95&#x00025; confidence interval 32&#x02013;63&#x00025;) achieved an objective response. The median duration of responses was 8 months, and the median survival time and the 1-year survival rate were 12.5 months and 56.8&#x00025;, respectively. Major toxicities were neutropenia and diarrhoea. Grade 3 or 4 neutropenia occurred in 70.5&#x00025; of the patients and one patient died of sepsis. Grade 3 or 4 diarrhoea was experienced in 25.0&#x00025;, but manageable by conventional therapy. In conclusion, fractionated administration of CPT-11 and CDDP was highly effective for advanced NSCLC with manageable toxicities. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>phase II study</kwd><kwd>irinotecan</kwd><kwd>cisplatin</kwd><kwd>fractionated administration</kwd><kwd>non-small-cell lung cancer</kwd></kwd-group></article-meta></front></article>


